{"id":"https://genegraph.clinicalgenome.org/r/e707ecf6-d1dc-40c2-a0e1-bcd5654e49f5v1.0","type":"EvidenceStrengthAssertion","dc:description":"*CAVIN1* (previously known as *PTRF*) was first reported in relation to autosomal recessive inherited congenital generalized lipodystrophy type 4 (CGL4, OMIM:613327) in 2009 (Hayashi et al., PMID: 19726876), with variants in affected individuals being in homozygous (n= 4) or compound heterozygous (n=1) status. Typically, CGL4 patients are characterized by some unique clinical features (PMIDs: 12116229), including congenital myopathy, cardiac arrythmias, congenital pyloric stenosis, gastrointestinal dysmotility, and skeletal abnormalities compared with other CGL subtypes. Elevated serum creatine kinase levels, and percussion-induced muscle mounding are also typical of CGL4 (PMIDs: 19726876, 20300641, 20684003, 20684003, 20638880, 24024685, 23489663, 25721873, 25994244, 27167729, 27144933, 27144934, 30476128, 32467771, 35405042, 35989241, 36946378, 38234231). At least 21 null mutations, including 8 nonsense and 13 frameshift variants, have been reported in at least 46 patients (reviewed in Akinci et al. PMID: 38234231) in several publications. Variants in this gene segregated with disease in at least 3 family members (PMIDs: 38234231, 20300641). For the purpose of this curation, 2 variants from Hayashi et al (PMID:19726876), 2 from Rajab et al (PMID: 20300641) and 8 from Akinci et al (PMID: 38234231) are included. More evidence is available in the literature, but the maximum score for genetic evidence (12 pts) has been reached. Initial mechanistic studies suggest that many of the mutations result in the absence of detectable CAVIN/PTRF protein, with subsequent perturbation of caveolin expression and localization leading to disrupted and/or reduced formation of caveolae (PMID: 19726876, 20300641, 27144934). This gene-disease relationship is also supported by animal models (PMIDs: 28289716,18840361) showing that Cavin1/PTRF is essential for caveolae formation in vivo in all tissues. *Cavin1*-knockout mice lack morphologically detectable caveolae in several cell types, including intestinal smooth muscle and skeletal muscle. As a characteristic of the lipodystrophic phenotype, these mice exhibit significantly reduced adipose tissue mass, elevated circulating triglyceride levels, glucose intolerance, and hyperinsulinemia (PMID: 18840361). *Cavin1* null mice also show reduced exercise capacity and muscle hypertrophy with increased fiber size and mass; however, these muscle tissues are fibrotic and exhibit impaired regeneration (PMID: 28289716). Experimental evidence: 6 points.  Total evidence:  18 points.  In summary, there is definitive evidence supporting the relationship between *CAVIN1* (previously known as *PTRF*) and autosomal recessive inherited congenital generalized lipodystrophy type 4.\nGene-Disease Validity Standard Operating Procedures (SOP) - SOP11.\n","dc:isVersionOf":"https://genegraph.clinicalgenome.org/r/e707ecf6-d1dc-40c2-a0e1-bcd5654e49f5","GCISnapshot":"https://genegraph.clinicalgenome.org/r/9676952d-3e95-4e05-ac04-04fc1b4ed7b3","calculatedEvidenceStrength":"Definitive","contributions":[{"id":"https://genegraph.clinicalgenome.org/r/9676952d-3e95-4e05-ac04-04fc1b4ed7b3_publish_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10016","date":"2025-01-16T18:42:49.887Z","role":"Publisher"},{"id":"https://genegraph.clinicalgenome.org/r/9676952d-3e95-4e05-ac04-04fc1b4ed7b3_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10016","date":"2025-01-16T17:00:00.000Z","role":"Approver"}],"curationReasons":["NewCuration"],"evidence":[{"id":"https://genegraph.clinicalgenome.org/r/9676952d-3e95-4e05-ac04-04fc1b4ed7b3_overall_genetic_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/cfbf28fd-773e-4a83-b5e7-83f8668fb340_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/823a9da9-c6a2-4ee6-bd78-e4c808532a85","type":"EvidenceLine","calculatedScore":3.0,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/823a9da9-c6a2-4ee6-bd78-e4c808532a85_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/38234231","allele":{"id":"https://genegraph.clinicalgenome.org/r/eabb1236-6dc1-4b6c-936e-6672a2c5ab2e","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_012232.6(CAVIN1):c.259C>T (p.Gln87Ter)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA399592212"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Homozygous"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":3.0},{"id":"https://genegraph.clinicalgenome.org/r/cfbf28fd-773e-4a83-b5e7-83f8668fb340","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/38234231","rdfs:label":"Akinci_2024_P4","ageType":"AgeAtDiagnosis","ageUnit":"Years","ageValue":9,"allele":{"id":"https://genegraph.clinicalgenome.org/r/eabb1236-6dc1-4b6c-936e-6672a2c5ab2e"},"ethnicity":{"id":"cg:NotHispanicOrLatino"},"firstTestingMethod":"Next generation sequencing panels","previousTesting":true,"previousTestingDescription":"Sequencing of PTRF/CAVI1 was performed with MiSeq V2 chemistry on MiSeq instrument (Illumina California).","sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/823a9da9-c6a2-4ee6-bd78-e4c808532a85_variant_evidence_item"}}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":3.0},{"id":"https://genegraph.clinicalgenome.org/r/64a9fe65-1f02-4670-adaf-c1cdaa4edcf3_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/13f7608b-f5db-4c3c-820c-c60cc08f8cad","type":"EvidenceLine","calculatedScore":4,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/13f7608b-f5db-4c3c-820c-c60cc08f8cad_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Absence of PTRF-CAVIN protein expression from FI_201 fibroblasts (Figure 4D) by western blot analysis.","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/13f7608b-f5db-4c3c-820c-c60cc08f8cad_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/20300641","allele":{"id":"https://genegraph.clinicalgenome.org/r/a2f7ddc5-32eb-481e-af6a-c7e93f63e3eb","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_012232.6(CAVIN1):c.160del (p.Val54CysfsTer2)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA891843509"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Homozygous"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":4},{"id":"https://genegraph.clinicalgenome.org/r/64a9fe65-1f02-4670-adaf-c1cdaa4edcf3","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/20300641","rdfs:label":"Rajab_Family I_201","allele":{"id":"https://genegraph.clinicalgenome.org/r/a2f7ddc5-32eb-481e-af6a-c7e93f63e3eb"},"sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/13f7608b-f5db-4c3c-820c-c60cc08f8cad_variant_evidence_item"}}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":3},{"id":"https://genegraph.clinicalgenome.org/r/8547e7de-159f-4e92-95ad-8a800b858d4a_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/a0507757-9a86-45de-8ed3-c1ea1d4b481f","type":"EvidenceLine","calculatedScore":3.0,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/a0507757-9a86-45de-8ed3-c1ea1d4b481f_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/38234231","allele":{"id":"https://genegraph.clinicalgenome.org/r/eabb1236-6dc1-4b6c-936e-6672a2c5ab2e"},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Homozygous"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":3.0},{"id":"https://genegraph.clinicalgenome.org/r/8547e7de-159f-4e92-95ad-8a800b858d4a","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/38234231","rdfs:label":"Akinci_2024_P3","ageType":"AgeAtOnset","ageUnit":"Months","ageValue":27,"allele":{"id":"https://genegraph.clinicalgenome.org/r/eabb1236-6dc1-4b6c-936e-6672a2c5ab2e"},"ethnicity":{"id":"cg:NotHispanicOrLatino"},"firstTestingMethod":"Next generation sequencing panels","phenotypes":["obo:HP_0002155","obo:HP_0003236","obo:HP_0009125","obo:HP_0003712"],"previousTesting":true,"previousTestingDescription":"Sequencing of PTRF/CAVI1 was performed with MiSeq V2 chemistry on MiSeq instrument (Illumina California).","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/a0507757-9a86-45de-8ed3-c1ea1d4b481f_variant_evidence_item"}}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":3.0},{"id":"https://genegraph.clinicalgenome.org/r/4f4f070f-3f33-4efb-9b69-832a5e8039f0_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/0e80d4a4-6d32-4fe9-b0c6-ae3e23d6e0bb","type":"EvidenceLine","calculatedScore":4,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/0e80d4a4-6d32-4fe9-b0c6-ae3e23d6e0bb_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Both immunohistochemistry and immunoblotting on skeletal muscle biopsy from Hayashi_P4 patient showed barely detectable levels of CAVIN1 as compared to control muscles. This loss is associated to dystrophic changes, deficiency and mislocalization of all 3 caveolin family members and reduction of caveolae structure.\nOverexpression of CAVIN1 c.696dup mutation in C2C12 myoblasts resulted in CAVIN1 altered localization and reduced interaction with caveolin 3.\nAkt phosphorylation at both T308 and S473 residues was elevated in the muscle of Hayashi_P4 as compared to controls, thus suggesting that the Akt pathway activation may explain, at least in partly, the muscle hypertrophy observed in this patient.\n","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/0e80d4a4-6d32-4fe9-b0c6-ae3e23d6e0bb_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/19726876","allele":{"id":"https://genegraph.clinicalgenome.org/r/5560ddd3-8d37-4eb6-966d-6f61ccc194e3","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_012232.6(CAVIN1):c.696dup (p.Lys233GlnfsTer?)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA626218368"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"paternityMaternityConfirmed":"No","zygosity":{"id":"cg:Homozygous"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":4},{"id":"https://genegraph.clinicalgenome.org/r/4f4f070f-3f33-4efb-9b69-832a5e8039f0","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/19726876","rdfs:label":"Hayashi_P4","ageType":"AgeAtReport","ageUnit":"Years","ageValue":27,"allele":{"id":"https://genegraph.clinicalgenome.org/r/5560ddd3-8d37-4eb6-966d-6f61ccc194e3"},"detectionMethod":"After PCR all exons and their flanking intronic regions of PTRF, CAV3, LMNA, AGPAT2, BSCL2, CAV1, PPARG, AKT2, and ZMPSTE24 Sanger sequencing was performed by using ABI PRISM 3100 automated sequencer (Applied Biosystems). Primer sequences are listed in Supplemental Table 3.","ethnicity":{"id":"cg:NotHispanicOrLatino"},"firstTestingMethod":"PCR","phenotypes":["obo:HP_0003557","obo:HP_0003560","obo:HP_0009125","obo:HP_0000007","obo:HP_0003593","obo:HP_0003236"],"previousTesting":false,"secondTestingMethod":"Sanger sequencing","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/0e80d4a4-6d32-4fe9-b0c6-ae3e23d6e0bb_variant_evidence_item"}}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":3},{"id":"https://genegraph.clinicalgenome.org/r/5d28dd5d-5389-49eb-b514-87e57e99de72_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/c3fdcbc7-3858-4639-a231-478a4e2e5078","type":"EvidenceLine","calculatedScore":3.0,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/c3fdcbc7-3858-4639-a231-478a4e2e5078_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/38234231","allele":{"id":"https://genegraph.clinicalgenome.org/r/eabb1236-6dc1-4b6c-936e-6672a2c5ab2e"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Homozygous"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":3.0},{"id":"https://genegraph.clinicalgenome.org/r/5d28dd5d-5389-49eb-b514-87e57e99de72","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/38234231","rdfs:label":"Akinci_2024_P2","ageType":"AgeAtOnset","ageUnit":"Years","ageValue":13,"allele":{"id":"https://genegraph.clinicalgenome.org/r/eabb1236-6dc1-4b6c-936e-6672a2c5ab2e"},"ethnicity":{"id":"cg:NotHispanicOrLatino"},"firstTestingMethod":"Next generation sequencing panels","phenotypes":["obo:HP_0002155","obo:HP_0003236","obo:HP_0003292","obo:HP_0003712","obo:HP_0009125"],"previousTesting":true,"previousTestingDescription":"Sequencing of PTRF/CAVI1 was performed with MiSeq V2 chemistry on MiSeq instrument (Illumina California).","sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/c3fdcbc7-3858-4639-a231-478a4e2e5078_variant_evidence_item"}}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":3.0},{"id":"https://genegraph.clinicalgenome.org/r/d15da5c8-d473-4c2a-a6c5-fb68cc9683e7_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/99906e14-4454-4869-81f1-944e0447fe33","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/99906e14-4454-4869-81f1-944e0447fe33_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Both immunohistochemistry and immunoblotting on skeletal muscle biopsy from Hayashi_P5 patient showed barely detectable levels of CAVIN1 as compared to control muscles. This loss is associated to dystrophic changes, deficiency and mislocalization of all 3 caveolin family members and reduction of caveolae structure. Overexpression of CAVIN1 c.525delG mutation in C2C12 myoblasts resulted in CAVIN1 intranuclear localization and lack of interaction with caveolin 3. Akt phosphorylation at both T308 and S473 residues was elevated in the muscle of Hayashi_P5 as compared to controls, thus suggesting that the Akt pathway activation may explain, at least in partly, the muscle hypertrophy observed in this patient.","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/99906e14-4454-4869-81f1-944e0447fe33_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/19726876","allele":{"id":"https://genegraph.clinicalgenome.org/r/d12510cb-7da3-4533-9593-972e4b3c9c13","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_012232.6(CAVIN1):c.526del (p.Glu176ArgfsTer?)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA891844157"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"paternityMaternityConfirmed":"No","zygosity":{"id":"cg:TwoVariantsInTrans"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/1cf2f7e3-42c3-4d17-85d1-9fba5a91f4a7","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/1cf2f7e3-42c3-4d17-85d1-9fba5a91f4a7_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Both immunohistochemistry and immunoblotting on skeletal muscle biopsy from Hayashi_P5 patient showed barely detectable levels of CAVIN1 as compared to control muscles. This loss is associated to dystrophic changes, deficiency and mislocalization of all 3 caveolin family members and reduction of caveolae structure.\nOverexpression of CAVIN1 c.696dup mutation in C2C12 myoblasts resulted in CAVIN1 altered localization and reduced interaction with caveolin 3.\nAkt phosphorylation at both T308 and S473 residues was elevated in the muscle of Hayashi_P5 as compared to controls, thus suggesting that the Akt pathway activation may explain, at least in partly, the muscle hypertrophy observed in this patient.","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/1cf2f7e3-42c3-4d17-85d1-9fba5a91f4a7_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/19726876","allele":{"id":"https://genegraph.clinicalgenome.org/r/5560ddd3-8d37-4eb6-966d-6f61ccc194e3"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"paternityMaternityConfirmed":"No","zygosity":{"id":"cg:TwoVariantsInTrans"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/d15da5c8-d473-4c2a-a6c5-fb68cc9683e7","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/19726876","rdfs:label":"Hayashi_P5","ageType":"AgeAtReport","ageUnit":"Years","ageValue":24,"allele":[{"id":"https://genegraph.clinicalgenome.org/r/d12510cb-7da3-4533-9593-972e4b3c9c13"},{"id":"https://genegraph.clinicalgenome.org/r/5560ddd3-8d37-4eb6-966d-6f61ccc194e3"}],"detectionMethod":"After PCR all exons and their flanking intronic regions of PTRF, CAV3, LMNA, AGPAT2, BSCL2, CAV1, PPARG, AKT2, and ZMPSTE24 Sanger sequencing was performed by using ABI PRISM 3100 automated sequencer (Applied Biosystems). Primer sequences are listed in Supplemental Table 3.","ethnicity":{"id":"cg:NotHispanicOrLatino"},"firstTestingMethod":"PCR","phenotypes":["obo:HP_0000007","obo:HP_0003236","obo:HP_0003593","obo:HP_0003560","obo:HP_0003557","obo:HP_0009125"],"previousTesting":false,"secondTestingMethod":"Sanger sequencing","sex":"Male","variant":[{"id":"https://genegraph.clinicalgenome.org/r/1cf2f7e3-42c3-4d17-85d1-9fba5a91f4a7_variant_evidence_item"},{"id":"https://genegraph.clinicalgenome.org/r/99906e14-4454-4869-81f1-944e0447fe33_variant_evidence_item"}]}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":3},{"id":"https://genegraph.clinicalgenome.org/r/9e12800a-d0fa-4a8b-8682-4dc76b52e27d_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/ec59d8b4-1feb-4c66-82ac-3f9d227326fa","type":"EvidenceLine","calculatedScore":3.0,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/ec59d8b4-1feb-4c66-82ac-3f9d227326fa_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/38234231","allele":{"id":"https://genegraph.clinicalgenome.org/r/a2f7ddc5-32eb-481e-af6a-c7e93f63e3eb"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Homozygous"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":3.0},{"id":"https://genegraph.clinicalgenome.org/r/9e12800a-d0fa-4a8b-8682-4dc76b52e27d","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/38234231","rdfs:label":"Akinci_2024_P28","ageType":"AgeAtDiagnosis","ageUnit":"Years","ageValue":2,"allele":{"id":"https://genegraph.clinicalgenome.org/r/a2f7ddc5-32eb-481e-af6a-c7e93f63e3eb"},"ethnicity":{"id":"cg:NotHispanicOrLatino"},"phenotypes":["obo:HP_0003712","obo:HP_0009125","obo:HP_0003236"],"sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/ec59d8b4-1feb-4c66-82ac-3f9d227326fa_variant_evidence_item"}}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":3.0},{"id":"https://genegraph.clinicalgenome.org/r/679f696d-c1c7-4cb8-aa23-2f02264e6641_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/a2430acc-828a-47e0-a054-172811a25cd1","type":"EvidenceLine","calculatedScore":3.0,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/a2430acc-828a-47e0-a054-172811a25cd1_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/38234231","allele":{"id":"https://genegraph.clinicalgenome.org/r/d4974d1e-0b93-4016-b717-0c13520b9bf0","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_012232.6(CAVIN1):c.192del (p.Val65Ter)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA2953902973"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Homozygous"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":3.0},{"id":"https://genegraph.clinicalgenome.org/r/679f696d-c1c7-4cb8-aa23-2f02264e6641","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/38234231","rdfs:label":"Akinci_2024_P16","ageType":"AgeAtDiagnosis","ageUnit":"Years","ageValue":17,"allele":{"id":"https://genegraph.clinicalgenome.org/r/d4974d1e-0b93-4016-b717-0c13520b9bf0"},"ethnicity":{"id":"cg:NotHispanicOrLatino"},"phenotypes":["obo:HP_0003712","obo:HP_0003236","obo:HP_0002155","obo:HP_0009125"],"sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/a2430acc-828a-47e0-a054-172811a25cd1_variant_evidence_item"}}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":3.0},{"id":"https://genegraph.clinicalgenome.org/r/2e4dd7db-4e5b-43b0-8e03-5d3d66e49221_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/aacf819c-d69f-4465-898d-c2516c755144","type":"EvidenceLine","calculatedScore":4,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/aacf819c-d69f-4465-898d-c2516c755144_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Both immunohistochemistry and immunoblotting on skeletal muscle biopsy from Hayashi_P2 patient showed barely detectable levels of CAVIN1 as compared to control muscles. This loss is associated to dystrophic changes, deficiency and mislocalization of all 3 caveolin family members and reduction of caveolae structure.\nOverexpression of CAVIN1 c.696dup mutation in C2C12 myoblasts resulted in CAVIN1 altered localization and reduced interaction with caveolin 3.\n\n","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/aacf819c-d69f-4465-898d-c2516c755144_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/19726876","allele":{"id":"https://genegraph.clinicalgenome.org/r/5560ddd3-8d37-4eb6-966d-6f61ccc194e3"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"paternityMaternityConfirmed":"No","zygosity":{"id":"cg:Homozygous"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":4},{"id":"https://genegraph.clinicalgenome.org/r/2e4dd7db-4e5b-43b0-8e03-5d3d66e49221","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/19726876","rdfs:label":"Hayashi_P2","ageType":"AgeAtReport","ageUnit":"Years","ageValue":14,"allele":{"id":"https://genegraph.clinicalgenome.org/r/5560ddd3-8d37-4eb6-966d-6f61ccc194e3"},"detectionMethod":"After PCR all exons and their flanking intronic regions of PTRF, CAV3, LMNA, AGPAT2, BSCL2, CAV1, PPARG, AKT2, and ZMPSTE24 Sanger sequencing was performed by using ABI PRISM 3100 automated sequencer (Applied Biosystems). Primer sequences are listed in Supplemental Table 3.","ethnicity":{"id":"cg:NotHispanicOrLatino"},"firstTestingMethod":"PCR","phenotypes":["obo:HP_0000007","obo:HP_0003560","obo:HP_0003236","obo:HP_0003557","obo:HP_0009125","obo:HP_0003593"],"previousTesting":false,"secondTestingMethod":"Sanger sequencing","sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/aacf819c-d69f-4465-898d-c2516c755144_variant_evidence_item"}}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":3},{"id":"https://genegraph.clinicalgenome.org/r/2029d73f-5752-4652-a152-b92f1a2850c2_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/b40e21e7-84f0-4f63-8b10-75592a862807","type":"EvidenceLine","calculatedScore":3.0,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/b40e21e7-84f0-4f63-8b10-75592a862807_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/38234231","allele":{"id":"https://genegraph.clinicalgenome.org/r/ede74140-2f4d-4695-9a34-b274c2262343","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_012232.6(CAVIN1):c.214C>T (p.Gln72Ter)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA399592412"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Homozygous"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":3.0},{"id":"https://genegraph.clinicalgenome.org/r/2029d73f-5752-4652-a152-b92f1a2850c2","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/38234231","rdfs:label":"Akinci_2024_P5","ageType":"AgeAtDiagnosis","ageUnit":"Years","ageValue":9,"allele":{"id":"https://genegraph.clinicalgenome.org/r/ede74140-2f4d-4695-9a34-b274c2262343"},"ethnicity":{"id":"cg:NotHispanicOrLatino"},"phenotypes":["obo:HP_0009125","obo:HP_0003712","obo:HP_0003236"],"previousTesting":false,"sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/b40e21e7-84f0-4f63-8b10-75592a862807_variant_evidence_item"}}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":3.0},{"id":"https://genegraph.clinicalgenome.org/r/eed6fdd9-8588-4b4a-becc-7998c0e72925_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/ef752caf-c0d6-4fe3-87b7-9cc3d862412b","type":"EvidenceLine","calculatedScore":3.0,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/ef752caf-c0d6-4fe3-87b7-9cc3d862412b_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/38234231","allele":{"id":"https://genegraph.clinicalgenome.org/r/1e54d423-c8da-44f8-b9d7-519148646521","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_012232.6(CAVIN1):c.649del (p.Arg217AlafsTer?)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA8575820"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Homozygous"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":3.0},{"id":"https://genegraph.clinicalgenome.org/r/eed6fdd9-8588-4b4a-becc-7998c0e72925","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/38234231","rdfs:label":"Akinci_2024_P15","ageType":"AgeAtDiagnosis","ageUnit":"Years","ageValue":14,"allele":{"id":"https://genegraph.clinicalgenome.org/r/1e54d423-c8da-44f8-b9d7-519148646521"},"ethnicity":{"id":"cg:NotHispanicOrLatino"},"phenotypes":["obo:HP_0009125","obo:HP_0002155","obo:HP_0003236","obo:HP_0003712"],"sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/ef752caf-c0d6-4fe3-87b7-9cc3d862412b_variant_evidence_item"}}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":3.0},{"id":"https://genegraph.clinicalgenome.org/r/38f6e7dd-3e54-41ae-b8c4-6434244b5949_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/6aa9301d-0823-4328-8fe9-6d4364adbe29","type":"EvidenceLine","calculatedScore":3.0,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/6aa9301d-0823-4328-8fe9-6d4364adbe29_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/38234231","allele":{"id":"https://genegraph.clinicalgenome.org/r/5d921f9e-1bfd-4063-86fe-d948f31482a5","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_012232.6(CAVIN1):c.698del (p.Lys233ArgfsTer?)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA2953902972"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Homozygous"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":3.0},{"id":"https://genegraph.clinicalgenome.org/r/38f6e7dd-3e54-41ae-b8c4-6434244b5949","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/38234231","rdfs:label":"Akinci_2024_P7","ageType":"AgeAtDiagnosis","ageUnit":"Months","ageValue":15,"allele":{"id":"https://genegraph.clinicalgenome.org/r/5d921f9e-1bfd-4063-86fe-d948f31482a5"},"ethnicity":{"id":"cg:NotHispanicOrLatino"},"phenotypes":["obo:HP_0003560","obo:HP_0003236","obo:HP_0009125"],"sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/6aa9301d-0823-4328-8fe9-6d4364adbe29_variant_evidence_item"}}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":3.0},{"id":"https://genegraph.clinicalgenome.org/r/277a57c0-2086-4815-b6cf-80da19513183_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/a3c5a4f0-7b51-4bc8-acdb-a2c59a5f2556","type":"EvidenceLine","calculatedScore":4,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/a3c5a4f0-7b51-4bc8-acdb-a2c59a5f2556_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Both immunohistochemistry and immunoblotting on skeletal muscle biopsy from Hayashi_P3 patient showed barely detectable levels of CAVIN1 as compared to control muscles. This loss is associated to dystrophic changes, deficiency and mislocalization of all 3 caveolin family members and reduction of caveolae structure.\nOverexpression of CAVIN1 c.696dup mutation in C2C12 myoblasts resulted in CAVIN1 altered localization and reduced interaction with caveolin 3.\nAkt phosphorylation at both T308 and S473 residues was elevated in the muscle of Hayashi_P1 as compared to controls, thus suggesting that the Akt pathway activation may explain, at least in partly, the muscle hypertrophy observed in this patient.\n","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/a3c5a4f0-7b51-4bc8-acdb-a2c59a5f2556_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/19726876","allele":{"id":"https://genegraph.clinicalgenome.org/r/5560ddd3-8d37-4eb6-966d-6f61ccc194e3"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"paternityMaternityConfirmed":"No","zygosity":{"id":"cg:Homozygous"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":4},{"id":"https://genegraph.clinicalgenome.org/r/277a57c0-2086-4815-b6cf-80da19513183","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/19726876","rdfs:label":"Hayashi_P3","ageType":"AgeAtReport","ageUnit":"Years","ageValue":10,"allele":{"id":"https://genegraph.clinicalgenome.org/r/5560ddd3-8d37-4eb6-966d-6f61ccc194e3"},"detectionMethod":"After PCR all exons and their flanking intronic regions of PTRF, CAV3, LMNA, AGPAT2, BSCL2, CAV1, PPARG, AKT2, and ZMPSTE24 Sanger sequencing was performed by using ABI PRISM 3100 automated sequencer (Applied Biosystems). Primer sequences are listed in Supplemental Table 3.","ethnicity":{"id":"cg:NotHispanicOrLatino"},"firstTestingMethod":"PCR","phenotypes":["obo:HP_0009125","obo:HP_0003557","obo:HP_0003236","obo:HP_0000007","obo:HP_0003560","obo:HP_0003593"],"previousTesting":false,"secondTestingMethod":"Sanger sequencing","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/a3c5a4f0-7b51-4bc8-acdb-a2c59a5f2556_variant_evidence_item"}}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":3},{"id":"https://genegraph.clinicalgenome.org/r/a85e559e-881f-4c31-b12d-9af43e18bc8a_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/e2ff19ad-c5c6-4bcf-aa71-05e7d73da8a5","type":"EvidenceLine","calculatedScore":3.0,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/e2ff19ad-c5c6-4bcf-aa71-05e7d73da8a5_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/38234231","allele":{"id":"https://genegraph.clinicalgenome.org/r/c5866c91-5b0b-49e1-a3de-aba65a993fcb","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_012232.6(CAVIN1):c.631G>T (p.Glu211Ter)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA399585156"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Homozygous"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":3.0},{"id":"https://genegraph.clinicalgenome.org/r/a85e559e-881f-4c31-b12d-9af43e18bc8a","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/38234231","rdfs:label":"Akinci_2024_P14","ageType":"AgeAtDiagnosis","ageUnit":"Years","ageValue":36,"allele":{"id":"https://genegraph.clinicalgenome.org/r/c5866c91-5b0b-49e1-a3de-aba65a993fcb"},"ethnicity":{"id":"cg:NotHispanicOrLatino"},"sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/e2ff19ad-c5c6-4bcf-aa71-05e7d73da8a5_variant_evidence_item"}}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":3.0},{"id":"https://genegraph.clinicalgenome.org/r/d269b02e-7f60-4bf5-b394-d00f22b9fba3_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/75f8f740-f822-4aba-855c-bbfb5c233b39","type":"EvidenceLine","calculatedScore":3.0,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/75f8f740-f822-4aba-855c-bbfb5c233b39_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/38234231","allele":{"id":"https://genegraph.clinicalgenome.org/r/5a5d7150-7f24-490e-aef8-c32a55dd2ccd","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_012232.6(CAVIN1):c.478_481dup (p.Lys161SerfsTer?)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA891844158"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Homozygous"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":3.0},{"id":"https://genegraph.clinicalgenome.org/r/d269b02e-7f60-4bf5-b394-d00f22b9fba3","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/38234231","rdfs:label":"Akinci_2024_P1","ageType":"AgeAtOnset","ageUnit":"Years","ageValue":11,"allele":{"id":"https://genegraph.clinicalgenome.org/r/5a5d7150-7f24-490e-aef8-c32a55dd2ccd"},"ethnicity":{"id":"cg:NotHispanicOrLatino"},"firstTestingMethod":"PCR","phenotypes":["obo:HP_0009125","obo:HP_0003712","obo:HP_0003236"],"previousTesting":true,"previousTestingDescription":"The coding region of the PTRF gene were amplified using gene-specific primers and subject to sanger sequencing.","secondTestingMethod":"Sanger sequencing","sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/75f8f740-f822-4aba-855c-bbfb5c233b39_variant_evidence_item"}}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":3.0},{"id":"https://genegraph.clinicalgenome.org/r/9676952d-3e95-4e05-ac04-04fc1b4ed7b3_seg_el","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/7e9f3f05-6b6b-4986-99f8-c628ec3eecae_family_segregation","type":"FamilyCosegregation","dc:description":"Homozygosity mapping and prioritization of 74 candidate genes for high expression in muscle and adipocytes suggested PTRF-CAVIN.  the coding region of PTRF-CAVIN and both 5' and 3'UTR were amplified an subjected to Sanger sequencing.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/20300641","rdfs:label":"Rajab_Family IV","estimatedLodScore":1.83,"family":{"id":"https://genegraph.clinicalgenome.org/r/7e9f3f05-6b6b-4986-99f8-c628ec3eecae","type":"Family","rdfs:label":"Rajab_Family IV","ethnicity":{"id":"cg:NotHispanicOrLatino"}},"meetsInclusionCriteria":true,"phenotype":[{"id":"obo:HP_0002021"},{"id":"obo:HP_0001324"},{"id":"obo:HP_0009125"},{"id":"obo:HP_0003719"}],"phenotypeNegativeAlleleNegative":5,"phenotypePositiveAllelePositive":3,"publishedLodScore":3,"sequencingMethod":{"id":"cg:CandidateGeneSequencing"}},{"id":"https://genegraph.clinicalgenome.org/r/1f65c7cc-8d26-4dc0-add3-2a3e31197bd8_family_segregation","type":"FamilyCosegregation","dc:description":"Homozygosity mapping and prioritization of 74 candidate genes for high expression in muscle and adipocytes suggested PTRF-CAVIN. the coding region of PTRF-CAVIN and both 5' and 3'UTR were amplified an subjected to Sanger sequencing.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/20300641","rdfs:label":"Rajab_Family VII","estimatedLodScore":1.45,"family":{"id":"https://genegraph.clinicalgenome.org/r/1f65c7cc-8d26-4dc0-add3-2a3e31197bd8","type":"Family","rdfs:label":"Rajab_Family VII","ethnicity":{"id":"cg:NotHispanicOrLatino"}},"meetsInclusionCriteria":true,"phenotype":[{"id":"obo:HP_0003719"},{"id":"obo:HP_0003712"},{"id":"obo:HP_0002021"},{"id":"obo:HP_0009125"},{"id":"obo:HP_0003236"},{"id":"obo:HP_0001324"},{"id":"obo:HP_0003552"},{"id":"obo:HP_0001371"}],"phenotypeNegativeAlleleNegative":2,"phenotypePositiveAllelePositive":3,"sequencingMethod":{"id":"cg:AllGenesSequencing"}},{"id":"https://genegraph.clinicalgenome.org/r/1969c31d-a707-461b-b909-ff7cba0d9d57_family_segregation","type":"FamilyCosegregation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/20300641","rdfs:label":"Rajab_Family III","family":{"id":"https://genegraph.clinicalgenome.org/r/1969c31d-a707-461b-b909-ff7cba0d9d57","type":"Family","rdfs:label":"Rajab_Family III","ethnicity":{"id":"cg:NotHispanicOrLatino"}},"phenotype":[{"id":"obo:HP_0009125"},{"id":"obo:HP_0002021"}],"phenotypeNegativeAlleleNegative":0,"phenotypePositiveAllelePositive":1},{"id":"https://genegraph.clinicalgenome.org/r/0f66db2e-fdf1-4bb3-914d-e2f397caee18_family_segregation","type":"FamilyCosegregation","dc:description":"Autosoma recessive condition with only 1 affected individual.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/20300641","rdfs:label":"Rajab_Family V","estimatedLodScore":0.25,"family":{"id":"https://genegraph.clinicalgenome.org/r/0f66db2e-fdf1-4bb3-914d-e2f397caee18","type":"Family","rdfs:label":"Rajab_Family V","ethnicity":{"id":"cg:NotHispanicOrLatino"}},"meetsInclusionCriteria":false,"phenotype":{"id":"obo:HP_0009125"},"phenotypeNegativeAlleleNegative":2,"phenotypePositiveAllelePositive":1},{"id":"https://genegraph.clinicalgenome.org/r/665e8a0c-53e4-420b-930f-807700f35565_proband_segregation","type":"FamilyCosegregation","dc:description":"In Rajab_Family I only 1 individual is affected.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/20300641","rdfs:label":"Rajab_Family I","estimatedLodScore":0.37,"family":{"id":"https://genegraph.clinicalgenome.org/r/665e8a0c-53e4-420b-930f-807700f35565","type":"Family","rdfs:label":"Rajab_Family I","ethnicity":{"id":"cg:NotHispanicOrLatino"},"member":{"id":"https://genegraph.clinicalgenome.org/r/64a9fe65-1f02-4670-adaf-c1cdaa4edcf3"}},"meetsInclusionCriteria":false,"phenotypeNegativeAlleleNegative":3,"phenotypePositiveAllelePositive":1,"phenotypes":["obo:HP_0003719","obo:HP_0000855","obo:HP_0001324","obo:HP_0003326","obo:HP_0001657","obo:HP_0003552","obo:HP_0002021","obo:HP_0000158","obo:HP_0003712","obo:HP_0001371","obo:HP_0002719","obo:HP_0003306","obo:HP_0001662","obo:HP_0009125","obo:HP_0002155","obo:HP_0001508","obo:HP_0001649","obo:HP_0003236","obo:HP_0033794","obo:HP_0006532"],"proband":{"id":"https://genegraph.clinicalgenome.org/r/64a9fe65-1f02-4670-adaf-c1cdaa4edcf3"}},{"id":"https://genegraph.clinicalgenome.org/r/aada1c20-6c8f-49ef-afb6-f3298fcc13a2_family_segregation","type":"FamilyCosegregation","dc:description":"Autosomal recessive conditions, with only include 1 affected individual.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/20300641","rdfs:label":"Rajab_Family II","estimatedLodScore":0.37,"family":{"id":"https://genegraph.clinicalgenome.org/r/aada1c20-6c8f-49ef-afb6-f3298fcc13a2","type":"Family","rdfs:label":"Rajab_Family II","ethnicity":{"id":"cg:NotHispanicOrLatino"}},"meetsInclusionCriteria":false,"phenotype":[{"id":"obo:HP_0001324"},{"id":"obo:HP_0033794"},{"id":"obo:HP_0003236"},{"id":"obo:HP_0001371"},{"id":"obo:HP_0003719"},{"id":"obo:HP_0003712"},{"id":"obo:HP_0003326"},{"id":"obo:HP_0001657"},{"id":"obo:HP_0003306"},{"id":"obo:HP_0009125"}],"phenotypeNegativeAlleleNegative":3,"phenotypePositiveAllelePositive":1},{"id":"https://genegraph.clinicalgenome.org/r/9a35a31b-f082-459e-bc36-13e9fe9c3bf8_family_segregation","type":"FamilyCosegregation","dc:description":"Autosomal recessive conditions with only 1 affected individual.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/20300641","rdfs:label":"Rajab_Family VI","estimatedLodScore":0.25,"family":{"id":"https://genegraph.clinicalgenome.org/r/9a35a31b-f082-459e-bc36-13e9fe9c3bf8","type":"Family","rdfs:label":"Rajab_Family VI","ethnicity":{"id":"cg:NotHispanicOrLatino"}},"meetsInclusionCriteria":false,"phenotype":{"id":"obo:HP_0003712"},"phenotypeNegativeAlleleNegative":2,"phenotypePositiveAllelePositive":1},{"id":"https://genegraph.clinicalgenome.org/r/c42c68d4-4487-494f-ad72-beedffa67b79_proband_segregation","type":"FamilyCosegregation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/38234231","rdfs:label":"Akinci_2024_F21","estimatedLodScore":3.61,"family":{"id":"https://genegraph.clinicalgenome.org/r/c42c68d4-4487-494f-ad72-beedffa67b79","type":"Family","rdfs:label":"Akinci_2024_F21","ethnicity":{"id":"cg:NotHispanicOrLatino"},"member":{"id":"https://genegraph.clinicalgenome.org/r/9e12800a-d0fa-4a8b-8682-4dc76b52e27d"}},"meetsInclusionCriteria":true,"phenotypePositiveAllelePositive":7,"phenotypes":["obo:HP_0003712","obo:HP_0002155","obo:HP_0009125","obo:HP_0003236"],"proband":{"id":"https://genegraph.clinicalgenome.org/r/9e12800a-d0fa-4a8b-8682-4dc76b52e27d"},"sequencingMethod":{"id":"cg:AllGenesSequencing"}}],"specifiedBy":"GeneValiditySegregationEvidenceCriteria","strengthScore":3},{"id":"https://genegraph.clinicalgenome.org/r/1f29b773-0519-477a-bb09-e60634a4275a_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/88a62f6d-707b-4be0-a8c5-3debaeff3789","type":"EvidenceLine","calculatedScore":4,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/88a62f6d-707b-4be0-a8c5-3debaeff3789_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Both immunohistochemistry and immunoblotting on skeletal muscle biopsy from Hayashi_P1 patient showed barely detectable levels of CAVIN1 as compared to control muscles. This loss is associated to dystrophic changes, deficiency and mislocalization of all 3 caveolin family members and reduction of caveolae structure.\nOverexpression of CAVIN1 c.696dup mutation in C2C12 myoblasts resulted in CAVIN1 altered localization and reduced interaction with caveolin 3.\nAkt phosphorylation at both T308 and S473 residues was elevated in the muscle of Hayashi_P1 as compared to controls, thus suggesting that the Akt pathway activation may explain, at least in partly, the muscle hypertrophy observed in this patient.\n","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/88a62f6d-707b-4be0-a8c5-3debaeff3789_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/19726876","allele":{"id":"https://genegraph.clinicalgenome.org/r/5560ddd3-8d37-4eb6-966d-6f61ccc194e3"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"paternityMaternityConfirmed":"No","zygosity":{"id":"cg:Homozygous"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":4},{"id":"https://genegraph.clinicalgenome.org/r/1f29b773-0519-477a-bb09-e60634a4275a","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/19726876","rdfs:label":"Hayashi_P1","ageType":"AgeAtReport","ageUnit":"Years","ageValue":8,"allele":{"id":"https://genegraph.clinicalgenome.org/r/5560ddd3-8d37-4eb6-966d-6f61ccc194e3"},"detectionMethod":"After PCR all exons and their flanking intronic regions of PTRF, CAV3, LMNA, AGPAT2, BSCL2, CAV1, PPARG, AKT2, and ZMPSTE24 Sanger sequencing was performed by using ABI PRISM 3100 automated sequencer (Applied Biosystems). Primer sequences are listed in Supplemental Table 3.","ethnicity":{"id":"cg:NotHispanicOrLatino"},"firstTestingMethod":"PCR","phenotypes":["obo:HP_0003593","obo:HP_0003557","obo:HP_0003236","obo:HP_0000007","obo:HP_0009125","obo:HP_0003560"],"previousTesting":false,"secondTestingMethod":"Sanger sequencing","sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/88a62f6d-707b-4be0-a8c5-3debaeff3789_variant_evidence_item"}}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":3}],"specifiedBy":"GeneValidityOverallGeneticEvidenceCriteria","strengthScore":12},{"id":"https://genegraph.clinicalgenome.org/r/9676952d-3e95-4e05-ac04-04fc1b4ed7b3_experimental_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/9676952d-3e95-4e05-ac04-04fc1b4ed7b3_model_rescue_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/0cbd89d3-9390-4e5c-91f2-18464e3db107","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/731501e8-09b8-46d1-9f2d-494f69e4a646","type":"Finding","dc:description":"Ding et al show that PTRF/cavin-1  knocked down mice exhibit: decreased ability to exercise, and muscle hypertrophy with increased muscle fiber size and muscle mass likely due to constitutive Akt pathway activation. The absence of PTRF/cavin-1 in mice cause a unique form of muscular dystrophy with a phenotype similar or identical to that seen in humans lacking this protein.\n\nexhibit lipo- and muscular dystrophy. ","dc:source":"https://pubmed.ncbi.nlm.nih.gov/28289716","rdfs:label":"Effects of cavin-1 deficiency on skeletal muscle fuction","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"}}],"specifiedBy":"GeneValidityNonHumanModelOrganismCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/974f3d57-d7ef-401d-a405-58627f87b8ba","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/b30c6ec9-3932-46d1-8137-df8f31107353","type":"Finding","dc:description":"Cavin-knockout mice are viable and of normal weight but have higher circulating triglyceride levels, significantly reduced adipose tissue mass, glucose intolerance, and hyperinsulinemiaâ€”characteristics that constitute a lipodystrophic phenotype.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/18840361","rdfs:label":"Cavin-knockout mice","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"}}],"specifiedBy":"GeneValidityNonHumanModelOrganismCriteria","strengthScore":2}],"specifiedBy":"GeneValidityOverallModelAndRescueEvidenceCriteria","strengthScore":4},{"id":"https://genegraph.clinicalgenome.org/r/9676952d-3e95-4e05-ac04-04fc1b4ed7b3_functional_alteration_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/ba4d9bbf-7023-4093-99f9-7b1c63ba3b51","type":"EvidenceLine","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/c0ef9115-c884-42a6-8c99-43e882ba42a7","type":"FunctionalAlteration","dc:description":"Skeletal muscle of patients shoved marked variation in fiber size, enlarged fibers with internalized nuclei, endomysial fibrosis, and few necrotic and regenerating fibers.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/19726876","rdfs:label":"Absence of detectable cavin/PTRF protein in skeletal muscle"}],"specifiedBy":"GeneValidityPatientCellFunctionalAlterationCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/059b8a1a-d23e-400a-8ad5-8b58f73b6788","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/3201d803-2dd1-46e9-b4a9-88fb7808ef00","type":"FunctionalAlteration","dc:description":"CAVIN1 mutants (i.e. c.525delG and c.696_697insC) and T7-tagged caveolin-3 or -1 were cotransfected in C2C12 myoblasts.  While  WT PTRF was detected at the cell membrane, the c.525delG mutant was detected as intranuclear aggregations and the c.696_697insC mutant was observed as microtubular filament network in cytoplasm.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/19726876","rdfs:label":"CAVIN1 mislocalization in transfected cells"}],"specifiedBy":"GeneValidityNonPatientCellFunctionalAlterationCriteria","strengthScore":0.5}],"specifiedBy":"GeneValidityOverallFunctionalAlterationEvidenceCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/9676952d-3e95-4e05-ac04-04fc1b4ed7b3_functional_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/32a2ad86-f095-4d68-afd5-c31a2b481c9f","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/40511569-28f5-4a28-91a4-4452ee12f216","type":"Finding","dc:description":"Both immunohistochemistry and immunoblotting on skeletal muscle biopsy patients showed barely detectable levels of CAVIN1.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/19726876","rdfs:label":"Immunohistochemistry and western blot","demonstrates":{"id":"cg:GeneExpressionB"}}],"specifiedBy":"GeneValidityGeneExpressionCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/dea66cef-8b2d-4a6c-acb5-72ff30d05f81","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/5272e874-8d7a-404b-a348-63bb6d3d70b8","type":"Finding","dc:description":"Cavin-1 protein was not detectable in fibroblasts from two probands with CGL4.\nIn addition, PTRF-mutated fibroblasts from the two probands showed decreased number of caveolae and increased autophagic flux","dc:source":"https://pubmed.ncbi.nlm.nih.gov/27144934","rdfs:label":"Western blot in probands fibroblasts","demonstrates":{"id":"cg:GeneExpressionB"}}],"specifiedBy":"GeneValidityGeneExpressionCriteria","strengthScore":0.5}],"specifiedBy":"GeneValidityOverallFunctionalEvidenceCriteria","strengthScore":1}],"specifiedBy":"GeneValidityOverallExperimentalEvidenceCriteria","strengthScore":6}],"evidenceStrength":"Definitive","sequence":9829,"specifiedBy":"GeneValidityCriteria11","strengthScore":18,"subject":{"id":"https://genegraph.clinicalgenome.org/r/-rEDlCLnSm4","type":"GeneValidityProposition","disease":"obo:MONDO_0006573","gene":"hgnc:9688","modeOfInheritance":"obo:HP_0000007"},"version":"1.0","websiteLegacyID":"https://genegraph.clinicalgenome.org/r/assertion_9676952d-3e95-4e05-ac04-04fc1b4ed7b3-","@context":{"@vocab":"https://genegraph.clinicalgenome.org/terms/","id":"@id","type":"@type","cg":"https://genegraph.clinicalgenome.org/terms/","dc":"http://purl.org/dc/terms/","obo":"http://purl.obolibrary.org/obo/","hgnc":"https://identifiers.org/hgnc:","rdfs":"http://www.w3.org/2000/01/rdf-schema#","cggv":"https://genegraph.clinicalgenome.org/r/gci/","evidenceStrength":{"@type":"@vocab"},"calculatedEvidenceStrength":{"@type":"@vocab"},"computedEvidenceStrength":{"@type":"@vocab"},"specifiedBy":{"@type":"@vocab"},"evidence":{"@container":"@set"},"disease":{"@type":"@vocab"},"gene":{"@type":"@vocab"},"phenotypes":{"@type":"@id"},"agent":{"@type":"@id"},"role":{"@type":"@vocab"},"modeOfInheritance":{"@type":"@vocab"},"sex":{"@type":"@vocab"},"direction":{"@type":"@vocab"},"ageType":{"@type":"@vocab"},"ageUnit":{"@type":"@vocab"},"dc:source":{"@type":"@id"},"curationReasons":{"@type":"@vocab","@container":"@set"},"GCISnapshot":{"@type":"@id"},"dc:isVersionOf":{"@type":"@id"},"websiteLegacyID":{"@type":"@id"}}}